Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CBST